Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years old~* Provided written consent for participation in the trial prior to any study-specific procedures or requirements~* Posterior uveitis or panuveitis associated with macular oedema defined as increased macular thickness (more than 250 mm assessed by Stratus TD-OCT or 300 mm with Cirrus SD-OCT ) and/or the presence of cystoid spaces in the macula, and the absence of epiretinal membranes.~* Patient with oral contraception~* Posterior uveitis or panuveitis associated with macular oedema~* Patients with histologically proven sarcoidosis or a presumed sarcoidosis. In case of a non caseating granuloma in biopsy tissues, the patients with presumed sarcoidosis meet at least 2 of the 4 following criteria: typical changes on chest radiography and computed tomography; predominantly CD4 lymphocytosis in bronchoalveolar lavage (BAL) fluid; elevated serum ACE levels; elevated gallium or 5 fluorodeoxyglucose uptake~Exclusion Criteria:~* Patients who do not fulfill the inclusion criteria~* Other causes of uveitis~* Extra ophthalmologic manifestations of sarcoidosis justifying corticosteroids~* Patients previously treated with immunosuppressive agents or corticosteroids of more than 10 mg daily over 15 days.~* Patients with life-threatening conditions~* Chronic hepatopathy or renal failure~* Uncontrolled diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methotrexate (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).